Home > Boards > US Listed > Biotechs >

Neoleukin Therapeutics Inc (NLTX)

NLTX RSS Feed
Add NLTX Price Alert      Hide Sticky   Hide Intro
Moderator: mick
Search This Board: 
Last Post: 9/5/2020 2:56:38 PM - Followers: 4 - Board type: Free - Posts Today: 0



 

NEOLEUKIN THERAPEUTICS, INC.

360-1616 Eastlake Avenue East

Seattle, WA 98102

(206) 732-2133
 https://www.neoleukin.com/
https://www.neoleukin.com/science/
https://www.neoleukin.com/careers/#overview
https://www.neoleukin.com/programs/
https://www.neoleukin.com/news/
http://investor.neoleukin.com/
 

Principal Scientist, Protein Expression and Optimization in Mammalian Systems

DESCRIPTION

Neoleukin Therapeutics is seeking an exceptional Principal Scientist to lead its efforts in the field of Mammalian Protein expression. The selected candidate will participate in research programs targeting the expression, characterization, and optimization of de novo designed protein therapeutics. The scope of the research will include (but is not limited to) production of complex recombinant proteins and biochemical, biophysical, and thermodynamic characterization. Examples of targets are cytokines, cell-signaling molecules, and soluble forms of membrane cytokine receptors.

The candidate must have at least five years of industry experience in expression, purification, characterization and optimization of recombinant proteins in mammalian systems, including the expression of human antibodies, cytokines, and cytokine receptors.

The appointed scientist will be responsible for designing and managing research programs in collaboration with senior management, as well as to translate our high-level strategic vision into a scientific reality. As an early-stage biotech company, Neoleukin thrives on developing an inspiring work environment that foremost embraces a collaborative team-based approach.


PRIMARY RESPONSIBILITIES

  • Application of existing biochemical, biophysical and thermodynamic tools for mammalian protein expression
    Purification of recombinant proteins using a variety of systems (ion exchange, size exclusion, affinity chromatography)
    Characterization of proteins using various methods, such as SDS-PAGE/CE-SDS, SEC-MALS, MS, and endotoxin testing
    Troubleshoot and optimize assays through data interpretation, identification of novel or alternate procedures and techniques
    Preparation of data summaries, reports, manuscripts, and presentations of research results
    Perform experiments with strong attention to detail and excellent documentation
    Determination and implementation of research team goals
    Building a collaborative network within Neoleukin Therapeutics and with its external research partner
    Lead a team of researchers and regularly interfacing with senior management


QUALIFICATIONS

  • Expertise in the fields of Biochemistry, Chemistry, Molecular or Cell Biology, or related fields in Life Sciences. PhD is highly desired
    Substantial proven experience in generation and characterization of recombinant proteins in heterologous systems is required,
    including Mammalian systems. Including: Protein Expression and Purification, Biophysics, Protein Structure determination,
    Protein Biochemistry, and/or protein engineering Experience in protein analytical techniques, including electrophoresis, Western Blot, ELISAs,
    Endotoxin assays, HPLC, FPLC, UV-Vis Spectrophotometry, Calorimetry (ITC/DSC), Fluorescence and Circular Dichroism Spectroscopy,
    Surface Plasmon Resonance (SPR) and Mass Spectrometry Proven exceptional record of research, including peer-reviewed publications in international journals
    Excellent written and oral communication and presentation skills
    Ability to work in a team environment encompassing multiple disciplines with excellent interpersonal and management skills.
    A strong desire to work in a highly dynamic environment is essential
    Ability to work independently, multi-task and meet deadlines in a fast-paced environment
    Committed to the values of integrity, scientific rigor, and transparency


APPLICATIONS CAN BE SUBMITTED TO CAREERS@NEOLEUKIN.COM

Neoleukin Therapeutics is proud to be an equal opportunity employer.
All applicants will be considered for employment without attention to race, color, religion, sex, sexual orientation, gender identity, national origin,
veteran or disability status, or age, and Neoleukin will not tolerate discrimination or harassment based on any of the above characteristics.

 
 
LTX SECURITY DETAILS

Share Structure

Market Cap Market Cap
498,851,080
05/14/2020
Authorized Shares
Not Available
 
Outstanding Shares
38,373,160  03/12/2020
 
 


https://www.otcmarkets.com/stock/NLTX/disclosure

https://www.otcmarkets.com/stock/NLTX/news

 https://www.otcmarkets.com/stock/NLTX/security

https://www.otcmarkets.com/stock/NLTX/profile

https://www.otcmarkets.com/stock/NLTX/quote

https://www.otcmarkets.com/stock/NLTX/overview



 *DISCLAIMER *The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
• We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.









 
NLTX
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NLTX News: Statement of Changes in Beneficial Ownership (4) 09/10/2020 04:28:51 PM
NLTX News: Initial Statement of Beneficial Ownership (3) 09/10/2020 04:23:59 PM
NLTX News: Current Report Filing (8-k) 09/10/2020 08:17:50 AM
NLTX News: Neoleukin Therapeutics Announces Appointment of Martin Babler to Board of Directors 09/10/2020 08:00:10 AM
NLTX News: Neoleukin Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference 09/09/2020 08:00:10 AM
PostSubject
#35   Neoleukin Therapeuti (NLTX) mick 09/05/20 02:56:38 PM
#34   Bullish!! Let’s Go!! tavito 08/19/20 07:15:03 PM
#33   Neoleukin Therapeuti (NLTX) mick 08/16/20 01:10:23 PM
#32   Looking great!! tavito 08/12/20 09:01:43 PM
#31   Neoleukin Therapeuti (NLTX) mick 07/25/20 01:41:09 PM
#30   Neoleukin Therapeuti (NLTX) mick 07/03/20 09:17:00 PM
#29   https://ih.advfn.com/stock-market/NASDAQ/neoleukin-therapeutics-NLTX/stock-news/ mick 07/02/20 07:14:15 PM
#28   Neoleukin Therapeuti (NLTX) mick 06/30/20 03:50:39 PM
#27   Neoleukin Therapeuti (NLTX) mick 06/27/20 06:54:52 PM
#26   Neoleukin Therapeuti (NLTX) mick 06/07/20 01:45:59 PM
#25   Neoleukin Therapeuti (NLTX) mick 05/28/20 01:03:23 AM
#24   Neoleukin Therapeuti (NLTX) mick 05/19/20 09:24:53 AM
#23   THAK YOU, $NLTX !!!!! mick 05/15/20 05:11:40 PM
#22   Currently no FDA-approved exosome products as of 12/6/19. Phosphene 05/15/20 04:16:18 PM
#21   thank you, trying figure relations to $CAPR , mick 05/15/20 03:25:01 PM
#20   Thank you for sharing Mick! Phosphene 05/15/20 02:39:18 PM
#19   Neoleukin Therapeutics Announces Multiple Presentations at American Association mick 05/15/20 11:33:02 AM
#18   “The merger with Aquinox is transformational for our mick 05/15/20 11:29:19 AM
#17   Neoleukin launched in January with the idea to mick 05/15/20 11:28:06 AM
#16   Vancouver, B.C.-based Aquinox Pharmaceuticals is set to buy mick 05/15/20 11:27:38 AM
#15   Neoleukin Therapeutics Announces Multiple Presentations at American Association mick 05/15/20 11:08:17 AM
#14   Cancer-fighting startup Neoleukin merging with Aquinox in $40M mick 05/15/20 11:07:48 AM
#13   * * $NLTX Video Chart 12-23-2019 * * ClayTrader 12/23/19 05:49:27 PM
#12   CEO Drachman bought $1 million dollars worth of Phosphene 12/22/19 08:23:47 PM
#11   * * $NLTX Video Chart 12-10-2019 * * ClayTrader 12/10/19 05:53:38 PM
#10   * * $NLTX Video Chart 12-09-2019 * * ClayTrader 12/09/19 05:37:00 PM
#9   Neoleukin Therapeutics Announces Scientific Advisory Board Phosphene 12/05/19 08:47:53 AM
#8   NLTX to Present at Piper Jaffray 31st Annual Phosphene 11/30/19 02:53:18 PM
#7   Neoleukin Therapeutics Announces Corporate Update and Third Quarter Phosphene 11/13/19 12:22:44 PM
#6   WOW Hmmmm I wonder why Mr Burkhard is hiring Work Harder 11/12/19 07:57:54 PM
#5   Jonathan Drachman, MD CHIEF EXECUTIVE OFFICER & PRESIDENT: Phosphene 11/10/19 06:46:36 PM
#4   Neoleukin Therapeutics uses advanced computational methods to build Phosphene 11/10/19 06:41:41 PM
#3   Upcoming Events and Milestones: Phosphene 11/10/19 06:39:32 PM
#2   The Baker Brothers hold 11,361,940 shares of NLTX. Phosphene 11/10/19 06:34:59 PM
#1   Cancer-fighting startup Neoleukin merging with Aquinox in $40M Phosphene 11/10/19 06:32:23 PM
PostSubject
Consent Preferences